ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Amgen’s Aranesp Sales Dropped By Half, Continue To Fall.

November 14, 2008

Ten-Year Breast Cancer Survival Improved In Past 60 Years, MD Anderson Study Finds

October 29, 2010

Gene Variant Associated With 44 Percent Cancer Risk Reduction

October 26, 2012

CCRAC Members Say Practicing Physicians Do Not Use Cancer Prevention Methods

August 24, 1979

In Brief: Walter To Retire, Search Starts For New DEA Deputy; Mary Fink Retires; NCCP Seeks Director

January 27, 1984

ACS Initiates New Colorectal Cancer Screening Campaign

November 18, 1983